The clinical use of lipid nanoparticles (LNPs) for drug delivery is currently limited by their tendency to accumulate in the liver. Tuning their biodistribution to reach other tissues and to target specific cell types in an organ remains a major challenge1,2. Writing in Nature, Lei et al.3 report their approach for engineering LNPs that specifically deliver therapeutic RNA to the pancreas — successfully targeting cell populations that were previously beyond the reach of LNPs, and unlocking avenues of research towards therapies that combat currently incurable pancreatic diseases.…